Chernett Amends 13G; Holds 10.23% of Oncology Institute (TOI)
Rhea-AI Filing Summary
Oncology Institute, Inc. amendment to a Schedule 13G reports that Jorey Chernett beneficially owned 10,115,944 shares of Common Stock as of the close of business on March 13, 2026, representing 10.23% of outstanding shares. The filing cites 98,839,144 Shares outstanding as of March 5, 2026 per the company’s Annual Report on Form 10-K filed March 12, 2026. The cover page shows the Reporting Person has sole voting and dispositive power over the 10,115,944 shares. The amendment is signed by Jorey Chernett on March 16, 2026.
Positive
- None.
Negative
- None.
Insights
Amendment confirms a >10% stake and sole control over reported shares.
The filing records that Jorey Chernett beneficially owns 10,115,944 shares, equal to 10.23% of the company based on the disclosed 98,839,144 outstanding shares. The cover-page entries list sole voting and dispositive power for the reported shares.
The ownership level surpasses common beneficial-ownership thresholds that can trigger disclosure obligations and may be relevant for governance discussions. Subsequent filings or amendments will show any changes in percentage or voting arrangements.
AI-generated analysis. How Rhea-AI works. Not financial advice.